Strategic Partners

Strategic partnerships are an important part of our business strategy to create value for investors and patients

In 2013, Catalyst and ISU Abxis, a leading Korean biopharmaceutical company (086890.KQ-KOSDAQ), formed a strategic collaboration to advance the development and commercialization of Catalyst's next-generation Factor IX development candidate CB 2679d for the prevention and treatment of bleeding in hemophilia B patients. The collaboration is focused on taking CB 2679d/ISU304 through IND-enabling pre-clinical development and Phase 1 clinical development in hemophilia B patients.

Catalyst is entitled to up front and milestone payments and has retained worldwide commercialization rights, except for ISU Abxis’ right of first refusal for commercialization rights in Korea, and subject to a future profit sharing arrangement.